GlassScriptPhysician profile
Tina Cochran
NPI 1265904825
$9,762.48
in general payments reported to CMS, 2019-2025
35 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $974 · 2022: $2,624 · 2023: $2,045 · 2024: $2,253 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,154 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,153.50 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,491.65 | 2021-2025 | |
| Novo Nordisk INC | $1,215.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $765.25 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $714.95 | 2021-2024 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $704.21 | 2022-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $686.39 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $585.61 | 2022-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $557.66 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $529.20 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $470.13 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Vanda Pharmaceuticals INC. | $390.07 | 2024-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $200.91 | 2024 | Voquezna |
| Pfizer INC. | $175.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.54 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $127.71 | 2022-2024 | Camzyos |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.